Diagnostic Performance Of I-123-Fp-Cit Spect Specific Binding Ratio In Progressive Supranuclear Palsy: Use Of Core Clinical Features And Mri For Comparison

OBJECTIVE. Progressive supranuelear palsy (PSP) is listed as a core clinical feature in the Movement Disorder Society 2017 criteria, along with ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction. Imaging evidence shows predominant midbrain atrophy and postsynaptic striatal dopaminergic degeneration as two supportive features. The purpose of this study was to investigate the diagnostic performance of I-123-N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-(4-iodophenyl) nortropane (I-123-FP-CIT) SPECT by comparing it with evaluation of core clinical features and MRI in the diagnosis of PSP.MATERIALS AND METHODS. The study included 53 patients with clinically suspected PSP who had undergone I-123-FP-CIT SPECT and MRI examinations. MR parkinsonism index (MRPI) was used as the MRI index. For the I-123-FP-CIT SPECT index, specific binding ratio (SBR) was calculated as the average of the right and left SBRs.RESULTS. In regard to core clinical features, ocular motor dysfunction was present in 15 of 20 (75.0%) patients with the diagnosis of probable PSP (p < 0.0001). Calculation of the diagnostic performance of the imaging parameters showed that MRPI (cutoff > 11.6) had 85.0% sensitivity, 100% specificity, and 94.3% accuracy. SBR (cutoff < 3.7) had 95.0% sensitivity, 36.4% specificity, and 58.5% accuracy.CONCLUSION. Iodine-123-labeled FP-CIT SPECT has high sensitivity, and MRI has high specificity in the diagnosis of PSP. Because these tools have complementary roles, reaching a more confident clinical diagnosis of PSP may be possible when both are used.